Pieris Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

SECNov 13 16:09 ET · Announcements

Pieris Pharmaceuticals Announces First Patient Dosed in SELVA Phase 3 Trial

TipRanksNov 7 08:53 ET

Express News | Palvella Therapeutics Announces First Patient Dosed in Selva Phase 3 Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Microcystic Lymphatic Malformations

ReutersNov 7 08:30 ET

Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN Rapamycin) for the Treatment of Microcystic Lymphatic Malformations

GlobeNewswireNov 7 08:30 ET

Express News | Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

ReutersOct 17 07:30 ET

Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

GlobeNewswireOct 15 07:30 ET